Soaanz Patent Expiration

Soaanz is a drug owned by Sarfez Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 06, 2033. Details of Soaanz's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10154963 Controlled-release formulations comprising Torsemide
Oct, 2033

(8 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Soaanz's patents.

Given below is the list of recent legal activities going on the following patents of Soaanz.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 17 Aug, 2022 US10154963
Surcharge for late Payment, Small Entity 17 Aug, 2022 US10154963
Maintenance Fee Reminder Mailed 08 Aug, 2022 US10154963
Change in Power of Attorney (May Include Associate POA) 17 Sep, 2021 US10154963
Correspondence Address Change 15 Sep, 2021 US10154963
Patent Issue Date Used in PTA Calculation 18 Dec, 2018 US10154963
Recordation of Patent Grant Mailed 18 Dec, 2018 US10154963
Email Notification 29 Nov, 2018 US10154963
Issue Notification Mailed 28 Nov, 2018 US10154963
Dispatch to FDC 14 Nov, 2018 US10154963

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Soaanz is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Soaanz's family patents as well as insights into ongoing legal events on those patents.

Soaanz's Family Patents

Soaanz has patent protection in a total of 2 countries. It has a significant patent presence in the US with 88.9% of its patents being US patents. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Soaanz.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Soaanz's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 06, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Soaanz Generics:

Torsemide is the generic name for the brand Soaanz. 10 different companies have already filed for the generic of Soaanz, with Strides Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Soaanz's generic





About Soaanz

Soaanz is a drug owned by Sarfez Pharmaceuticals Inc. Soaanz uses Torsemide as an active ingredient. Soaanz was launched by Sarfe Pharms in 2021.

Approval Date:

Soaanz was approved by FDA for market use on 14 June, 2021.

Active Ingredient:

Soaanz uses Torsemide as the active ingredient. Check out other Drugs and Companies using Torsemide ingredient

Dosage:

Soaanz is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
60MG TABLET Discontinued ORAL
20MG TABLET Discontinued ORAL